TMCnet News
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' OptionRA’ANANA, Israel and NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its public offering of 1,463,414 ordinary shares, at a public offering price of $41.00 per share. In addition, the underwriters exercised their option to purchase an additional 219,512 ordinary shares at the public offering price, less the underwriting discounts and commissions. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the public offering are expected to be approximately $64 million. All ordinary shares sold in this offering were offered by the Company. Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering. Ladenburg Thalmann & Co. Inc. and National Securities Corporation acted as co-managers for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 18, 2018. The offering was made only by means of a prospectus, which is part of the effective registration statement. Copies of the prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: [email protected]; or from Cowen and Company, LLC, c/o Bradridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About UroGen Pharma Ltd. Forward Looking Statements UROGEN CONTACTS: Christine Cassiano Kate Bechtold |